XGN
USDExagen Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$11.080
Kõrge
$11.500
Madal
$10.500
Maht
1.42M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
237.0M
Tööstusharu
Diagnostics & Research
Riik
United States
Kauplemisstatistika
Keskmine maht
0.23M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
BTIG Maintains Buy on Exagen, Raises Price Target to $15
BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $13 to $15.
Exagen Inc. Reports Strong Q3 2025 Results
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15
Canaccord Genuity analyst Kyle Mikson maintains Exagen with a Buy and raises the price target from $11 to $15.
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's
BTIG Maintains Buy on Exagen, Raises Price Target to $13
BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $11 to $13.
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.